<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Milad Nazarzadeh - Academic CV</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: #333;
            max-width: 1000px;
            margin: 0 auto;
            padding: 20px;
            background-color: #f5f5f5;
        }
        
        .container {
            background-color: white;
            padding: 40px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
        }
        
        header {
            border-bottom: 3px solid #2c3e50;
            padding-bottom: 20px;
            margin-bottom: 30px;
        }
        
        h1 {
            color: #2c3e50;
            font-size: 2.5em;
            margin-bottom: 10px;
        }
        
        .subtitle {
            color: #7f8c8d;
            font-size: 1.2em;
            margin-bottom: 15px;
        }
        
        .contact-info {
            display: flex;
            flex-wrap: wrap;
            gap: 20px;
            margin-top: 15px;
        }
        
        .contact-info a {
            color: #3498db;
            text-decoration: none;
        }
        
        .contact-info a:hover {
            text-decoration: underline;
        }
        
        section {
            margin-bottom: 30px;
        }
        
        h2 {
            color: #2c3e50;
            border-bottom: 2px solid #3498db;
            padding-bottom: 10px;
            margin-bottom: 20px;
            font-size: 1.8em;
        }
        
        .content-block {
            margin-bottom: 20px;
        }
        
        h3 {
            color: #34495e;
            margin-bottom: 5px;
        }
        
        .date {
            color: #7f8c8d;
            font-style: italic;
            margin-bottom: 10px;
        }
        
        ul {
            margin-left: 20px;
            margin-top: 10px;
        }
        
        li {
            margin-bottom: 8px;
        }
        
        footer {
            text-align: center;
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid #ddd;
                    
        .publication-item {
            margin-bottom: 25px;
            padding: 15px;
            background-color: #f9f9f9;
            border-left: 4px solid #3498db;
            border-radius: 4px;
        }
        
        .pub-title {
            color: #2c3e50;
            margin-bottom: 8px;
            font-size: 1.05em;
        }
        
        .pub-authors {
            color: #555;
            margin-bottom: 10px;
            font-size: 0.95em;
            line-height: 1.4;
        }
        
        .pub-summary {
            color: #666;
            font-size: 0.95em;
            line-height: 1.6;
            margin-top: 8px;
        }
        
        .publication-note {
            background-color: #e8f4f8;
            padding: 12px;
            border-radius: 4px;
            margin-bottom: 20px;
            font-size: 0.95em;
        }
            color: #7f8c8d;
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Milad Nazarzadeh</h1>
            <p class="subtitle"> Clinical Epidemiologist & Biostatistician | Senior Research Fellow in Cardiovascular and Genetic Epidemiology</p>
            <div class="contact-info">
                <span>ðŸ“§ Email: milad.nazarzadeh@wrh.ox.ac.uk</span>
                <span>ðŸ”— <a href="https://www.linkedin.com/in/milad-nazarzadeh-2a9305b3" target="_blank">LinkedIn</a></span>
                <span>ðŸ’» <a href="https://github.com/miladnazarzadeh" target="_blank">GitHub</a></span>
            </div>
        </header>

        <section>
            <h2>About Me</h2>
            <p>  Milad Nazarzadeh is a Senior Research Fellow in Cardiovascular and Genetic Epidemiology at the University of Oxford. His research integrates multidisciplinary methodologies, including individual participant data (IPD) meta-analysis, genetic data analysis, electronic health records, and artificial intelligence, to generate robust evidence on cardiovascular risk factors, treatments, and preventive strategies. His key areas of expertise include blood pressure, diabetes, valvular heart diseases, cardiovascular risk management, pharmacogenomics, and pharmacoepidemiology.

Milad earned his DPhil from the University of Oxford, where he was awarded an Immediate Postdoctoral Research Fellowship by the British Heart Foundation. His current research focuses on valvular heart diseases, an underexplored area of cardiovascular medicine, with the goal of advancing our understanding and identifying innovative treatment strategies. He is particularly interested in designing and conducting randomised controlled trials (RCTs) to test novel treatments and explore drug repurposing opportunities in cardiovascular medicine. Additionally, Milad is passionate about leveraging OMICs data to drive drug discovery and repurposing efforts, aiming to uncover new therapeutic approaches for cardiovascular diseases.

Beyond his work in cardiovascular research, Milad has a keen interest in exploring the therapeutic potential of psychedelics, particularly in relation to mental health and chronic disease management. He is enthusiastic about investigating the emerging intersections of psychedelic research with cardiovascular health and broader healthcare innovation.</p>
        </section>

        <section>
            <h2>Research Interests</h2>
            <ul>
                <li>Clinical Epidemiology</li>
                <li>Hypertension</li>
                <li>Valvular Heart Disease</li>
                <li>Genetics and Metabolomics in Cardiovascular Diseases</li>
                <li>Drug Target Discovery </li>
                <li>Mental Health</li>
            </ul>
        </section>

        <section>
            <h2>Education</h2>
            <div class="content-block">
                <h3>Your Degree</h3>
                <p class="date">Year - Year</p>
                <p>Institution Name</p>
            </div>
        </section>

        <section>
            <h2>Professional Experience</h2>
            <div class="content-block">
                <h3>Current Position</h3>
                <p class="date">Year - Present</p>
                <p>Institution/Organisation</p>
                <ul>
                    <li>Key responsibility or achievement</li>
                    <li>Key responsibility or achievement</li>
                </ul>
            </div>
        </section>

        <section>
            <h2>Publications</h2>
            <div class="content-block">
                <p class="publication-note">Selected publications from 76 peer-reviewed articles. For a complete list, visit <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nazarzadeh+M" target="_blank">PubMed</a>.</p>
                
                <div class="publication-item">
                    <p class="pub-title"><strong>1. Lancet. 2021 May 152197181879-1887.</strong> Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data.</p>
                    <p class="pub-authors">Nazarzadeh M, Pinho-Gomes AC, Bidel Z, Canoy D, Basu S, Dehghan A, Hassaine A, Chalmers J, Macmahon S, Woodward M, Teo K, Davis BR, Pepine CJ, Rahimi K; Blood Pressure Lowering Treatment Trialists Collaboration.</p>
                    <p class="pub-summary"><em>Importance:</em> This landmark study involving 348,854 participants demonstrated that blood pressure-lowering treatment significantly reduces cardiovascular events regardless of baseline blood pressure levels. The findings support a risk-based rather than threshold-based approach to hypertension management, potentially expanding treatment eligibility and preventing thousands of cardiovascular events globally.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>2. Curr Cardiol Rep. 2022 Jul;24(7):851-860.</strong> How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease?</p>
                    <p class="pub-authors">Canoy D, Nazarzadeh M, Copland E, Bidel Z, Rao S, Li Y, Rahimi K.</p>
                    <p class="pub-summary"><em>Importance:</em> This meta-analysis of individual data from 344,716 participants revealed that for each 5-mmHg reduction in systolic blood pressure, cardiovascular event risk fell by 10%, with consistent benefits across patients with and without previous cardiovascular disease. These findings establish clear quantitative targets for blood pressure reduction in clinical practice, regardless of patient history.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>3. Eur Heart J. 2023 Nov 7;44(42):4448-4457.</strong> Sodium-based paracetamol impact on blood pressure, cardiovascular events, and all-cause mortality.</p>
                    <p class="pub-authors">Rao S, Nazarzadeh M, Canoy D, Li Y, Huang J, Mamouei M, Salimi-Khorshidi G, Schutte AE, Neal B, Smith GD, Rahimi K.</p>
                    <p class="pub-summary"><em>Importance:</em> Using deep learning analysis of 475,442 UK patients, this study found no evidence that sodium-based paracetamol increases blood pressure or cardiovascular risk in routine clinical practice, contradicting previous concerns. This reassuring evidence supports the continued safe use of effervescent paracetamol formulations, addressing an important medication safety question affecting millions of users.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>4. Heart. 2023 Jul 27;109(16):1216-1222.</strong> Systolic blood pressure, chronic obstructive pulmonary disease and cardiovascular risk.</p>
                    <p class="pub-authors">Rao S, Nazarzadeh M, Li Y, Canoy D, Mamouei M, Salimi-Khorshidi G, Rahimi K.</p>
                    <p class="pub-summary"><em>Importance:</em> This cohort study of 39,602 COPD patients identified a monotonic association between systolic blood pressure and cardiovascular events, with risk increasing progressively above 120 mmHg. The findings demonstrate that blood pressure management remains crucial in COPD patients, a population often under-represented in cardiovascular trials.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>5. Hypertension. 2023 Mar;80(3):598-607.</strong> Systolic Blood Pressure and Cardiovascular Risk in Patients With Diabetes: A Prospective Cohort Study.</p>
                    <p class="pub-authors">Rao S, Li Y, Nazarzadeh M, Canoy D, Mamouei M, Hassaine A, Salimi-Khorshidi G, Rahimi K.</p>
                    <p class="pub-summary"><em>Importance:</em> Using deep learning to analyse 49,000 diabetic patients, this study found a monotonic relationship between blood pressure and cardiovascular outcomes without evidence of a J-curve, with lowest risk at <120 mmHg. These findings challenge traditional blood pressure targets in diabetes and suggest potential benefits of more intensive blood pressure control in this high-risk population.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>6. Lancet Oncol. 2021 Apr;22(4):558-570.</strong> Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.</p>
                    <p class="pub-authors">Copland E, Canoy D, Nazarzadeh M, et al.; Blood Pressure Lowering Treatment Trialists Collaboration.</p>
                    <p class="pub-summary"><em>Importance:</em> This comprehensive meta-analysis of 260,447 participants found no consistent evidence that antihypertensive medications increase cancer risk, providing reassurance about long-term safety. The findings address a critical safety concern and support continued use of blood pressure-lowering medications for cardiovascular protection without fear of oncological harm.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>7. Genome Med. 2021 Mar 4;13(1):38.</strong> Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study.</p>
                    <p class="pub-authors">Nazarzadeh M, Pinho-Gomes AC, Bidel Z, Canoy D, Dehghan A, Smith Byrne K, Bennett DA, Smith GD, Rahimi K.</p>
                    <p class="pub-summary"><em>Importance:</em> Using Mendelian randomization with data from one million Europeans, this study established that elevated blood pressure causally increases atrial fibrillation risk, with effects varying by genetic susceptibility. The genetic evidence supports blood pressure reduction as a preventive strategy for atrial fibrillation, particularly in genetically susceptible individuals.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>8. Heart. 2022 Jul 27;108(16):1281-1289.</strong> Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis.</p>
                    <p class="pub-authors">Canoy D, Copland E, Nazarzadeh M, et al.; Blood Pressure Lowering Treatment Trialists Collaboration.</p>
                    <p class="pub-summary"><em>Importance:</em> This analysis of 363,684 participants showed maximal blood pressure reduction at 12 months with gradual attenuation over time, with consistent effects across diverse patient characteristics. The findings highlight the need for treatment strategies to sustain long-term blood pressure reductions and inform optimal timing for treatment intensification.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>9. PLoS Med. 2021 Jun 1;18(6):e1003599.</strong> Blood pressure-lowering treatment for prevention of cardiovascular events in patients with atrial fibrillation.</p>
                    <p class="pub-authors">Pinho-Gomes AC, Azevedo L, Copland E, Canoy D, Nazarzadeh M, et al.; Blood Pressure Lowering Treatment Trialists Collaboration.</p>
                    <p class="pub-summary"><em>Importance:</em> This meta-analysis of 188,570 participants demonstrated that blood pressure-lowering treatment effectively reduces cardiovascular events in atrial fibrillation patients, with benefits consistent with the general population. The findings support proactive blood pressure management in atrial fibrillation, a condition where treatment benefits were previously uncertain.</p>
                </div>

                <div class="publication-item">
                    <p class="pub-title"><strong>10. PLoS Med. 2018 Nov 20;15(11):e1002695.</strong> Predicting the risk of emergency admission with machine learning: Development and validation using linked electronic health records.</p>
                    <p class="pub-authors">Rahimian F, Salimi-Khorshidi G, Payberah AH, Tran J, Ayala Solares R, Raimondi F, Nazarzadeh M, Canoy D, Rahimi K.</p>
                    <p class="pub-summary"><em>Importance:</em> Using machine learning on 4.6 million patient records, this study achieved substantially improved prediction of emergency hospital admissions compared to traditional methods. The validated models demonstrate how artificial intelligence can identify high-risk patients for targeted interventions, potentially reducing emergency department burden and improving healthcare resource allocation.</p>
                </div>

                <p style="margin-top: 30px; font-style: italic; color: #666;"><strong>Additional Key Publications:</strong> Research contributions span blood pressure management, cardiovascular disease prevention, genetic epidemiology, drug target Mendelian randomisation, systematic reviews and meta-analyses, environmental health, cancer epidemiology, and advanced statistical methodologies. Full publication list available on <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nazarzadeh+M" target="_blank">PubMed</a>.</p>            </div>
        </section>

        <section>
            <h2>Skills</h2>
            <ul>
                <li><strong>Programming:</strong> R, Python, SQL</li>
                <li><strong>Statistical Analysis:</strong> Mendelian Randomisation, Machine Learning, Biostatistics</li>
                <li><strong>Tools:</strong> Git/GitHub, R Studio, SPSS</li>
                <li><strong>Research:</strong> Scientific Writing, Manuscript Editing, Literature Review</li>
            </ul>
        </section>

        <footer>
            <p>&copy; 2025 Milad Nazarzadeh. All rights reserved.</p>
            <p>Last updated: November 2025</p>
        </footer>
    </div>
</body>
</html>
